TUKYSA (tucatinib), FDA Approved for Treatment of Advanced Unresectable or Metastatic HER2 Positive Breast Cancer, Available at Biologics by McKesson

CARY, N.C., April 20, 2020 —Biologics by McKesson, an independent specialty pharmacy for oncology and other rare and complex therapeutic areas, has been selected by Seattle Genetics as a specialty pharmacy provider for TUKYSATM (tucatinib) for the treatment of HER2 positive breast cancer.
Source: McKesson News - Category: Information Technology Source Type: news